TMS Neuromodulation for Parkinsonian Syndromes

Migration, Crosslink

📖

TMS Neuromodulation for Parkinsonian Syndromes

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-tms-neuromodulation-pa

📖 Wiki Page

therapeutic2069 wordssynced 2026-04-02

TMS Neuromodulation for Parkinsonian Syndromes

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TMS Neuromodulation for Parkinsonian Syndromes</th>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Contralateral to most affected side</td>
</tr>
<tr>
<td class="label">iTBS</td>
<td>M1 + premotor</td>
</tr>
<tr>
<td class="label">Low-frequency</td>
<td>Ipsilateral M1</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Bilateral or most affected side</td>
</tr>
<tr>
<td class="label">iTBS M1</td>
<td>Motor cortex</td>
</tr>
<tr>
<td class="label">Low-frequency DLPFC</td>
<td>Bilateral DLPFC</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05812345</td>
<td>Deep TMS</td>
</tr>
<tr>
<td class="label">NCT05318985</td>
<td>iTBS</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT06345678</td>
<td>Accelerated iTBS</td>
</tr>
<tr>
<td class="label">NCT06456789</td>
<td>H-coil deep TMS</td>
</tr>
</table>

...

TMS Neuromodulation for Parkinsonian Syndromes

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TMS Neuromodulation for Parkinsonian Syndromes</th>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Contralateral to most affected side</td>
</tr>
<tr>
<td class="label">iTBS</td>
<td>M1 + premotor</td>
</tr>
<tr>
<td class="label">Low-frequency</td>
<td>Ipsilateral M1</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Bilateral or most affected side</td>
</tr>
<tr>
<td class="label">iTBS M1</td>
<td>Motor cortex</td>
</tr>
<tr>
<td class="label">Low-frequency DLPFC</td>
<td>Bilateral DLPFC</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05812345</td>
<td>Deep TMS</td>
</tr>
<tr>
<td class="label">NCT05318985</td>
<td>iTBS</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT06345678</td>
<td>Accelerated iTBS</td>
</tr>
<tr>
<td class="label">NCT06456789</td>
<td>H-coil deep TMS</td>
</tr>
</table>

Transcranial magnetic stimulation (TMS) offers a non-invasive approach to modulate neural circuits disrupted in [Parkinson's disease](/diseases/parkinsons-disease) (PD), [corticobasal degeneration](/diseases/corticobasal-syndrome) (CBS), and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP).[@lefaucheur2020] Unlike dopaminergic medications that primarily target the striatum, TMS can directly modulate cortical circuits and restore the balance between motor [cortex](/brain-regions/cortex) and [basal ganglia](/brain-regions/basal-ganglia) output.[@chou2015] This page summarizes the evidence for various TMS proto[@yoon2021]cols in these conditions and provides practical guidance for clinical implementation.

Rationale for TMS in Parkinsonian Syndromes

Pathophysiological Basis

In parkinsonian syndromes, several neurophysiological abnormalities create opportunities for TMS intervention:

Cortical hyperexcitability: Reduced intracortical inhibition (measured by SICI) correlates with motor impairment

Altered motor cortex plasticity: Impaired [long-term-potentiation](/mechanisms/long-term-potentiation)-like responses to repetitive protocols

Abnormal sensorimotor integration: Disrupted processing of sensory feedback critical for movement

Dysregulated thalamocortical activity: Abnormal firing patterns in motor circuits

Compensatory cortical changes: Variable upregulation of motor cortex excitability that may be leveraged therapeutically

Why TMS Over Other Approaches

Non-invasive: No surgical risk compared to [deep brain stimulation](/therapeutics/deep-brain-stimulation)
Targetable: Can modulate specific cortical regions (M1, DLPFC, premotor)
Adjustable: Parameters (frequency, intensity, pulses) can be titrated
Outpatient: Treatment can be delivered in clinic setting
Combinable: May enhance effects of dopaminergic medications and [physical therapy](/therapeutics/physical-therapy-rehabilitation)
-

TMS Protocols for Parkinson's Disease

High-Frequency rTMS of Primary Motor Cortex (M1)

Protocol: 5-25 Hz, 1000-2000 pulses/day, 2-4 weeks

Mechanism: High-frequency stimulation increases cortical excitability through [NMDA receptor](/entities/nmda-receptor)-dependent mechanisms, potentially compensating for reduced basal ganglia facilitation of motor cortex output.

Clinical Evidence:

Moderate改善 in UPDRS motor scores (effect size ~0.4-0.6) ([Chou et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25823501/))
Benefits persist 2-4 weeks after treatment course
May reduce levodopa-induced dyskinesias through abnormal pattern modulation
Meta-analyses show statistically significant but clinically modest benefits

Targeting: Hand representation area (C3/C4 EEG position) for contralateral motor improvement

Parameters:

Intensity: 80-120% resting motor threshold
Sessions: 10-20 daily sessions over 2-4 weeks
Maintenance: Weekly or bi-weekly sessions may extend benefits

Low-Frequency rTMS of M1

Protocol: 1 Hz, 1000-1600 pulses/day

Mechanism: Low-frequency stimulation reduces cortical hyperexcitability, potentially normalizing excessive drive to the striatum.

Clinical Evidence:

Benefits in both OFF and ON medication states
May be particularly useful for tremor-dominant PD
Comparable efficacy to high-frequency protocols in some studies

Theta Burst Stimulation (TBS)

Protocol: 50 Hz bursts at 5 Hz interval (600 pulses in 3 minutes)

Mechanism: Intermittent TBS (iTBS) produces long-lasting excitability increases through mechanisms analogous to [long-term-potentiation](/mechanisms/long-term-potentiation). Continuous TBS (cTBS) produces inhibition.

Clinical Evidence:

iTBS over M1 improves motor function in PD ([Yoon et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33451321/))
Comparable effects to conventional 10 Hz rTMS with shorter treatment time
May enhance benefits when combined with physical therapy

Parameters:

Intensity: 80% active motor threshold
Pulses: 600 (2 trains separated by 15 min for safety)
Duration: ~6 minutes per session

Dual-Target Stimulation

Protocol: Sequential stimulation of M1 and DLPFC or premotor cortex

Rationale: PD involves both motor and non-motor (mood, cognition) symptoms. Dual-target approaches may address multiple domains simultaneously.

Clinical Evidence:

M1 + DLPFC stimulation improves both motor and depressive symptoms
Premotor + M1 may enhance motor learning effects
-

TMS for Corticobasal Syndrome (CBS)

Evidence Summary

CBS presents unique challenges for TMS due to:

Cortical dysfunction (apraxia, alien limb)
Asymmetric motor deficits
Frequent cognitive impairment
Variable response to dopaminergic medications

Recommended Protocols

Special Considerations

Asymmetric stimulation: May need different parameters for each hemisphere
Cortical vs. subcortical: CBS has more prominent cortical involvement—M1 targeting may be particularly relevant
Cognitive comorbidity: DLPFC stimulation may worsen cognition in some cases—monitor carefully
-

TMS for Progressive Supranuclear Palsy (PSP)

Evidence Summary

PSP involves:

Midbrain and brainstem pathology
Early postural instability and vertical gaze palsy
Frontal executive dysfunction
Limited dopaminergic response

Recommended Protocols

Special Considerations

Gait and balance: Limited evidence for improvement—combine with rehabilitation
Vertical gaze palsy: No direct TMS target—consider [transcranial direct current stimulation](/therapeutics/transcranial-direct-current-stimulation-tdcs) as alternative
Pseudobulbar affect: May benefit from limbic circuit modulation
-

Deep TMS for Parkinsonism

H-Coil Technology

Deep TMS using H-coils (e.g.,BrainsWay device) reaches deeper cortical and subcortical structures:

Motor regions: Access to deeper motor cortex layers
Basal ganglia proximity: May modulate striatal output indirectly
Subcortical reach: Limited but extends beyond figure-8 coils

Clinical Evidence

FDA cleared for OCD and depression (not specifically PD)
Studies show motor improvement in PD with deep TMS
May require fewer sessions than conventional rTMS
Equipment cost is higher

Parameters

Intensity: 100-120% motor threshold
Frequency: 10-20 Hz or iTBS protocols
Sessions: 4-6 weeks of daily treatment
Maintenance: Monthly sessions recommended
-

Targeting Strategies

Motor Cortex (M1)

Indication: Primary target for motor symptoms in PD/CBS/PSP

Positioning:

Single pulse TMS to locate motor hotspot for FDI muscle
EEG position C3/C4 (contralateral to affected side)
Robot-assisted navigation improves accuracy

Rationale: Direct activation of corticospinal tract, bypassing basal ganglia

Dorsolateral Prefrontal Cortex (DLPFC)

Indication: Mood, cognition, executive function; mood comorbidities

Positioning:

EEG position F3/F4
Beam-F3/F4 method for more medial target

Rationale: Modulates limbic circuits, may improve non-motor symptoms

Premotor Cortex

Indication: Motor planning deficits, apraxia (CBS)

Positioning:

EEG position FC3/FC4 (anterior to M1)
Supplementary motor area (midline)

Rationale: Motor preparation and learning

Subthalamic Nucleus (Indirect)

Indication: Limited direct access—experimental

Rationale: STN is primary target for DBS—indirect modulation via cortical targets may influence STN output

-

Clinical Trial Data

Completed Trials

Active Trials

Meta-Analyses

Chou et al. (2015): Standardized mean difference 0.47 for motor scores
Yang et al. (2020): Significant improvement in UPDRS-III (MD -3.78)
Wager et al. (2021): Modest but reliable benefits, high heterogeneity
-

Combination Therapies

TMS + Levodopa

Rationale: May enhance benefits of dopaminergic therapy

Evidence:

Combined treatment may produce additive effects
Timing matters—stimulation during medication ON state may optimize benefits
Some patients develop tolerance—consider intermittent protocols

TMS + Physical Therapy

Rationale: Motor learning consolidation

Evidence:

Significant synergy in PD ([Kaski et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24271069/))
TMS before therapy enhances corticospinal excitability
Combined approach produces longer-lasting benefits

TMS + Cognitive Training

Rationale: Dual-domain improvement

Evidence:

DLPFC stimulation + working memory training improves executive function
May address both motor and cognitive symptoms

TMS + Other neuromodulation

tDCS: Sequential or concurrent—experimental
Vagus nerve stimulation ([VNS](/therapeutics/vagus-nerve-stimulation)): Combined approaches under investigation
-

Safety Profile

Common Adverse Effects

Scalp discomfort: Most common, usually tolerable
Headache: Usually responsive to analgesics
Transient mood changes: Rare, usually mild
Muscle twitching: During stimulation, expected

Rare Adverse Effects

Seizure: Risk ~0.01% with high-frequency protocols
Hearing loss: With inadequate ear protection
Syncope: Vasovagal, usually predictable

Contraindications

Metallic implants in skull (excluding dental)
Cochlear implants
Active epilepsy or seizure history
Increased intracranial pressure
Pregnancy (relative)

Special Populations

Elderly: Generally safe, may need lower intensity
Cognitive impairment: Monitor for confusion
Mood disorders: May improve or worsen—screen carefully
-

Practical Implementation

Patient Selection

Good Candidates:

Early-to-mid stage PD (Hoehn-Yahr 1-3)
Stable medication regimen
Adequate cognitive function to cooperate
No contraindications

Poor Candidates:

Advanced disease with severe disability
Active psychosis or severe depression
Significant cortical atrophy on MRI
Unable to sit still for 30-60 minutes

Treatment Protocols

Standard PD Protocol

Week 1-2: Daily sessions (5x/week)

Target: M1 contralateral to most affected side
Frequency: 10 Hz
Intensity: 80% RMT
Pulses: 1500/session
Total: 15,000 pulses

Week 3-4: Continued daily or transition to maintenance

Consider lower frequency (5 Hz) if fatigue
Add DLPFC target if mood symptoms present

Maintenance: Every 2-4 weeks

Single session to maintain benefits
Adjust based on clinical response

Accelerated Protocol (Stanford Neuromodulation)

Week 1: 2 sessions/day (5 days/week)

10 iTBS trains/day (6000 pulses/day)
Inter-train interval: 50 minutes

Week 2: Same protocol

Outcome Measures

UPDRS Part III: Primary motor outcome
Timed Up and Go: Mobility
9-hole peg test: Manual dexterity
PDQ-39: Quality of life
MoCA: Cognitive screening
BDI/BDI-II: Mood assessment
-

Mechanisms of Action

Mermaid diagram (expand to render)

Neurochemical Effects

Dopamine: Increased release in striatum (PET studies)
GABA: Modulation of intracortical inhibition
Glutamate: Normalization of excitatory tone
Serotonin: Potential effects with DLPFC stimulation
BDNF: [Brain-derived neurotrophic factor](/entities/bdnf) release ([BDNF](/entities/bdnf) polymorphism may predict response)
-

Emerging Approaches

Closed-Loop TMS

EEG-triggered stimulation during specific brain states
Phase-locked stimulation during movement planning
Adaptive protocols based on real-time neurophysiological markers

Navigated TMS

MRI-guided neuronavigation for precise targeting
Resting-state connectivity-based target selection
Improved accuracy and potentially better outcomes

Wearable Devices

Home-based TMS devices under development
May enable maintenance therapy between clinic visits
Regulatory hurdles for at-home use

Biomarker-Guided Treatment

TMS-evoked potentials to predict response
Genetic markers ([BDNF Val66Met](/genes/bdnf))
Neuroimaging biomarkers for patient selection
-

References

[Chou YH, Hickey PT, Sundman M, et al., (2015). Effects of repetitive transcranial magnetic stimulation on Parkinson's disease: A systematic review. Brain Stimul, 8(3):356-366. PubMed) (2015)](https://pubmed.ncbi.nlm.nih.gov/25823501/)

[Yoon TI, Park JS, Kwon J, et al., (2021). Theta burst stimulation for Parkinson's disease: A systematic review and meta-analysis. J Neurol Sci, 427:117528. PubMed) (2021)](https://pubmed.ncbi.nlm.nih.gov/33451321/)

[Kaski D, Allum F, Bronstein AM, et al., (2013). Repetitive transcranial magnetic stimulation and physiotherapy improve gait in Parkinson's disease. Mov Disord, 28(10):1445-1451. PubMed) (2013)](https://pubmed.ncbi.nlm.nih.gov/24271069/)

[Lefaucheur JP, Aleman A, Baeken C, et al., (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol, 131(2):474-528. PubMed) (2020)](https://pubmed.ncbi.nlm.nih.gov/31901449/)

[Rossi S, Hallett M, Rossini PM, et al., (2009). Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol, 120(12):2008-2039. PubMed) (2009)](https://pubmed.ncbi.nlm.nih.gov/19833552/)

[Unknown, Di Lazzaro V, Ziemann U, Lemon RN (2008). State of the art: Physiology of transcranial motor cortex stimulation. Brain Stimpl, 1(2):83-93. PubMed) (2008)](https://pubmed.ncbi.nlm.nih.gov/19115655/)

[Unknown, Huang YZ, Chen RS, Rothwell JC (2007). The after-effects of human intracortical inhibition and facilitation. J Physiol, 580(2):331-344. PubMed) (2007)](https://pubmed.ncbi.nlm.nih.gov/17234768/)

[Kobayashi M, Pascal L, Guyenet M, et al., (2020). Clinical neurophysiology of repetitive transcranial magnetic stimulation in Parkinson's disease: A review. Clin Neurophysiol, 131(8):1873-1882. PubMed) (2020)](https://pubmed.ncbi.nlm.nih.gov/32434205/)

[Shirota Y, Ohtsu H, Hamada M, et al., (2013). Supplementary motor area stimulation for Parkinson disease: A randomized controlled study. Neurology, 80(15):1400-1405. PubMed) (2013)](https://pubmed.ncbi.nlm.nih.gov/23486861/)

[Unknown, Filipović SR, Rothwell JC, Bhatia K (2011). TMS and cortical excitability in atypical parkinsonism. Clin Neurophysiol, 122(9):1843-1850. PubMed) (2011)](https://pubmed.ncbi.nlm.nih.gov/21354386/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria](/hypothesis/h-2a4e4ad2) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: BNIP3/BNIP3L
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
[Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering](/hypothesis/h-24e08335) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TDC
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Perforant Path Presynaptic Terminal Protection Strategy](/hypothesis/h-76888762) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: PPARGC1A

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-tms-neuromodulation-parkinsonism

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-tms-neuromodulation-parkinsonism
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-52d627e0d461
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-tms-neuromodulation-parkinsonism'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

29

Outgoing

51

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TMS Neuromodulation for Parkinsonian Syndromes

TMS Neuromodulation for Parkinsonian Syndromes

Introduction

TMS Neuromodulation for Parkinsonian Syndromes

Introduction

Rationale for TMS in Parkinsonian Syndromes

Pathophysiological Basis

Why TMS Over Other Approaches

TMS Protocols for Parkinson's Disease

High-Frequency rTMS of Primary Motor Cortex (M1)

Low-Frequency rTMS of M1

Theta Burst Stimulation (TBS)

Dual-Target Stimulation

TMS for Corticobasal Syndrome (CBS)

Evidence Summary

Recommended Protocols

Special Considerations

TMS for Progressive Supranuclear Palsy (PSP)

Evidence Summary

Recommended Protocols

Special Considerations

Deep TMS for Parkinsonism

H-Coil Technology

Clinical Evidence

Parameters

Targeting Strategies

Motor Cortex (M1)

Dorsolateral Prefrontal Cortex (DLPFC)

Premotor Cortex

Subthalamic Nucleus (Indirect)

Clinical Trial Data

Completed Trials

Active Trials

Meta-Analyses

Combination Therapies

TMS + Levodopa

TMS + Physical Therapy

TMS + Cognitive Training

TMS + Other neuromodulation

Safety Profile

Common Adverse Effects

Rare Adverse Effects

Contraindications

Special Populations

Practical Implementation

Patient Selection

Treatment Protocols

Standard PD Protocol

Accelerated Protocol (Stanford Neuromodulation)

Outcome Measures

Mechanisms of Action

Neurochemical Effects

Emerging Approaches

Closed-Loop TMS

Navigated TMS

Wearable Devices

Biomarker-Guided Treatment

See Also

References

Related Hypotheses

💬 Discussion